This definition appears very rarely
and is found in the following Acronym Finder categories:
We have 1 other definition for BPUR
in our Acronym Attic
Samples in periodicals archive:
July 17 /PRNewswire-FirstCall/ -- Biopure Corporation announced that it has received notice from The Nasdaq Stock Market, by letter dated July 17, 2009, that its common stock would be delisted from Nasdaq.
Biopure Corporation (Nasdaq: BPUR) has issued further comment regarding the provisional opinion letter that the company received from the United Kingdom Commission on Human Medicines.
KAG624) CARL RAUSCH, CEO of BIOPURE CORPORATION (BPUR), describes the company's business and its background; prospects for the industry, with positive and negative trends; competitive threats; strategic opportunities for the firm including its marketing plans and acquisition potential; management strength and organization; and the financial prospects of the firm looking forward.
Biopure Corporation (Nasdaq: BPUR) announced today that the independent Data and Safety Monitoring Board (DSMB) for the company's Phase II clinical trial of Hemopure(R) [hemoglobin glutamer - 250 (bovine)] in trauma patients has completed its first scheduled interim analysis of blinded study data and recommended that the trial continue without modification.
Biopure Corporation (Nasdaq:BPUR) will announce its financial results for the first fiscal quarter ended January 31, 2004, on Thursday, February 19, 2004, after the market closes.
June 30 /PRNewswire-FirstCall/ -- Biopure Corporation announced that it has received notice from The Nasdaq Stock Market, by letter dated June 24, 2009, that it is out of compliance with the Nasdaq Marketplace Rules and its common stock may be delisted.
Biopure Corporation (Nasdaq: BPUR) announced today that the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) has validated the marketing authorization application (MAA) the company submitted on July 10, 2006 for Hemopure(R) [hemoglobin glutamer - 250 (bovine)] for the treatment of acutely anemic adult orthopedic surgery patients under 80 years of age.
com) has filed a class action against Biopure Corporation ("Biopure" or the "Company")(NASDAQ:BPUR), Thomas A.